PT Diagnos Laboratorium Utama (DGNS) Fundamentals 2026 — P/E 85.8x, Revenue Analysis | SniperIQ
PT Diagnos Laboratorium Utama (DGNS) is a ID-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of Rp316.3B, trading at Rp230.00 on the JKT. This SniperIQ fundamentals page covers PT Diagnos Laboratorium Utama's valuation (P/E 85.8x, P/B 1.4x), profitability (net margin 2.0%), revenue (Rp166.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Diagnos Laboratorium Utama's market cap?
PT Diagnos Laboratorium Utama (DGNS) has a market capitalization of approximately Rp316.3B, trading at Rp230.00 on the JKT. Market cap moves with the live share price.
What is PT Diagnos Laboratorium Utama's P/E ratio?
PT Diagnos Laboratorium Utama's trailing twelve-month P/E ratio is 85.8x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Diagnos Laboratorium Utama?
PT Diagnos Laboratorium Utama runs a net profit margin of 2.0%, a gross margin of 45.4%, and an operating margin of 3.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Diagnos Laboratorium Utama generate?
PT Diagnos Laboratorium Utama reported revenue of Rp166.6B for fiscal year 2025, with net income of Rp2.9B and earnings per share (EPS) of 2.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Diagnos Laboratorium Utama pay a dividend?
PT Diagnos Laboratorium Utama does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Diagnos Laboratorium Utama financially healthy?
PT Diagnos Laboratorium Utama carries a debt-to-equity ratio of 0.39x and a current ratio of 2.89x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Diagnos Laboratorium Utama a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Diagnos Laboratorium Utama (DGNS) the key facts are: market cap Rp316.3B, P/E 85.8x, revenue Rp166.6B, 52-week range 136-382. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Diagnos Laboratorium Utama's full fundamentals live
Get PT Diagnos Laboratorium Utama's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.